These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 1503438)
1. Phase I clinical studies of S-1108: safety and pharmacokinetics in a multiple-administration study with special emphasis on the influence on carnitine body stores. Nakashima M; Uematsu T; Oguma T; Yoshida T; Mizojiri K; Matsuno S; Yamamoto S Antimicrob Agents Chemother; 1992 Apr; 36(4):762-8. PubMed ID: 1503438 [TBL] [Abstract][Full Text] [Related]
2. Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. Totsuka K; Shimizu K; Konishi M; Yamamoto S Antimicrob Agents Chemother; 1992 Apr; 36(4):757-61. PubMed ID: 1503437 [TBL] [Abstract][Full Text] [Related]
3. Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. Shimizu K; Saito A; Shimada J; Ohmichi M; Hiraga Y; Inamatsu T; Shimada K; Tanimura M; Fujita Y; Nishikawa T Antimicrob Agents Chemother; 1993 May; 37(5):1043-9. PubMed ID: 8517691 [TBL] [Abstract][Full Text] [Related]
4. Disposition of S-1108, a new oral cephem antibiotic, and metabolic fate of pivalic acid liberated from [pivaloyl-14C]S-1108 in rats and dogs. Mizojiri K; Futaguchi S; Norikura R; Katsuyama Y; Nagasaki T; Yoshimori T; Nakanishi M Antimicrob Agents Chemother; 1995 Jul; 39(7):1445-53. PubMed ID: 7492083 [TBL] [Abstract][Full Text] [Related]
5. [Effect of cefditoren pivoxil on carnitine metabolism in pediatric patients]. Fujii R; Chiba S; Numazaki K; Mori T; Terashima I; Meguro H; Mori A; Toyonaga Y; Sunakawa K; Satoh Y Jpn J Antibiot; 1993 Oct; 46(10):926-37. PubMed ID: 8254895 [TBL] [Abstract][Full Text] [Related]
6. [Influence of multiple-dose administration of cefetamet pivoxil on blood and urinary concentrations of carnitine and effects of simultaneous administration of carnitine with cefetamet pivoxil]. Nakashima M; Kosuge K; Ishii I; Ohtsubo M Jpn J Antibiot; 1996 Oct; 49(10):966-79. PubMed ID: 8986559 [TBL] [Abstract][Full Text] [Related]
7. Preferential elimination of pivalate with supplemental carnitine via formation of pivaloylcarnitine in man. Melegh B; Sumegi B; Sherry AD Xenobiotica; 1993 Nov; 23(11):1255-61. PubMed ID: 8310709 [TBL] [Abstract][Full Text] [Related]
8. Determination of pivaloylcarnitine in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Konishi M; Hashimoto H J Pharm Sci; 1992 Oct; 81(10):1038-41. PubMed ID: 1432617 [TBL] [Abstract][Full Text] [Related]
9. Hypocarnitinemia Observed in an Infant Treated with Short-Term Administration of Antibiotic Containing Pivalic Acid. Nakazaki K; Ogawa E; Ishige M; Ishige N; Fuchigami T; Takahashi S Tohoku J Exp Med; 2018 Apr; 244(4):279-282. PubMed ID: 29628457 [TBL] [Abstract][Full Text] [Related]
10. Impact on carnitine homeostasis of short-term treatment with the pivalate prodrug cefditoren pivoxil. Brass EP; Mayer MD; Mulford DJ; Stickler TK; Hoppel CL Clin Pharmacol Ther; 2003 Apr; 73(4):338-47. PubMed ID: 12709724 [TBL] [Abstract][Full Text] [Related]
11. Formation of pivaloylcarnitine in heart and brown adipose tissue in the rat. Diep QN; Bøhmer T; Skrede S Biochim Biophys Acta; 1995 Jan; 1243(1):65-70. PubMed ID: 7827109 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of multiple-dose cefprozil and comparison with cefaclor. Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA Antimicrob Agents Chemother; 1990 Jun; 34(6):1198-203. PubMed ID: 2393281 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males. Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571 [TBL] [Abstract][Full Text] [Related]
15. Impaired ketogenesis in carnitine depletion caused by short-term administration of pivalic acid prodrug. Abrahamsson K; Eriksson BO; Holme E; Jodal U; Lindstedt S; Nordin I Biochem Med Metab Biol; 1994 Jun; 52(1):18-21. PubMed ID: 7917463 [TBL] [Abstract][Full Text] [Related]
16. Carnitine and glucuronic acid conjugates of pivalic acid. Vickers S; Duncan CA; White SD; Ramjit HG; Smith JL; Walker RW; Flynn H; Arison BH Xenobiotica; 1985 Jun; 15(6):453-8. PubMed ID: 4036169 [TBL] [Abstract][Full Text] [Related]
17. Surprising causes of C5-carnitine false positive results in newborn screening. Boemer F; Schoos R; de Halleux V; Kalenga M; Debray FG Mol Genet Metab; 2014 Jan; 111(1):52-4. PubMed ID: 24291264 [TBL] [Abstract][Full Text] [Related]
18. Plasma and urine pharmacokinetics of free and of short-chain carnitine after administration of carnitine in man. Segre G; Bianchi E; Corsi M; D'Iddio S; Ghirardi O; Maccari F Arzneimittelforschung; 1988 Dec; 38(12):1830-4. PubMed ID: 3245856 [TBL] [Abstract][Full Text] [Related]
19. Formation of pivaloylcarnitine in isolated rat heart cells. Diep QN; Brørs O; Bøhmer T Biochim Biophys Acta; 1995 Nov; 1259(2):161-5. PubMed ID: 7488636 [TBL] [Abstract][Full Text] [Related]
20. Children's toxicology from bench to bed--Liver injury (1): Drug-induced metabolic disturbance--toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism. Ito T J Toxicol Sci; 2009; 34 Suppl 2():SP217-22. PubMed ID: 19571472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]